Mumbai, July 23 -- Revenue from operations declined 5.55% YoY to Rs 8,070.5 crore in the quarter ended 30 June 2026.

Profit before tax (PBT) dropped 70.98% YoY to Rs 552.6 crore in Q1 FY27.

EBITDA slipped 55.72% to Rs 1,008.8 crore in Q1 FY27 compared with Rs 2,278.4 crore in Q1 FY26. EBITDA margin contracted to 12.5% in Q1 FY27 as against 26.7% in Q1 FY26.

Revenue from the Global Generics segment declined 4.79% year-on-year to Rs 7,199.3 crore during the quarter.

Revenue from the North America business fell 35.38% YoY to Rs 2,204.8 crore, mainly due to lower sales of Lenalidomide. The company launched six new products in the region during the quarter.

Revenue from the India business increased 16.76% YoY to Rs 1,717.7 crore, supporte...